Optimal design of clinical trials with computer simulation based on results of earlier trials, illustrated with a lipodystrophy trial in HIV patients

Journal of Biomedical Informatics

Volumn 41, Issue 6, 2008, Pages 1053-1061

  Abbas, Ismail ^a   Rovira, Joan ^b   Casanovas, Josep ^a   Greenfield, Tony ^c  

^a Department d'Estadistica i Investigacio Operativa   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Middle Cottage   (United Kingdom)

Author keywords

Clinical trials; Optimal design; Simulation models

Indexed keywords

CHOLESTEROL; COMPUTATIONAL METHODS; DESIGN; OPTIMAL SYSTEMS; POPULATION STATISTICS;

CHOLESTEROL LEVELS; CLINICAL TRIALS; CONVENTIONAL APPROACHES; HIV PATIENTS; LIPODYSTROPHY; OPTIMAL DESIGN; OPTIMAL DESIGNS; PRIOR KNOWLEDGES; REAL WORLDS; RECRUITMENT RATES; SIMULATION MODELS; STATISTICAL POWERS; SURROGATE MARKERS; TOTAL COSTS;

COMPUTER SIMULATION;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMPUTER SIMULATION; COST; HIV ASSOCIATED LIPODYSTROPHY; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; METHODOLOGY; PRIORITY JOURNAL; PROCESS DESIGN; TREATMENT WITHDRAWAL;

CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; RESEARCH DESIGN;

EID: 55749100553     PISSN: 15320464     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbi.2008.04.008     Document Type: Article

References (15)

1. Fleming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 7 (1996) 605-613
2. Eisenhauer E.A. Phase I and phase II trials of novel anti-cancer agents: endpoints, efficacy and existentialism. Ann Oncol 9 (1998) 1047-1052
3. Stone A., Wheeler C., Carroll K., and Barge A. Optimising randomised phase II trials assessing tumor progression. Contemp Clin Trials 28 2 (2007) 146-152
4. Lockwood P., Ewy W., Hermann D., and Holford N. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease. Pharm Res 23 9 (2006) 2050-2059
5. Schruben DL, Schruben LW. Event graph modeling using SIGMA for Windows. 4th version. 2002.
6. Negredo E., Cruz L., Paredes R., Ruiz L., Fumaz C.R., Bonjoch A., et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in subjects with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis (2002) 34
7. Romeu J, Tural C, Sirera G. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors [abstract 1293]. In: Programs and abstracts of the 39th interscience conference on antimicrobial agents and chemotherapy (San Francisco); 1999. p. 499.
8. Abbas I., Rovira J., and Casanovas J. Validation by simulation of a clinical trial model using the standardized mean and variance criteria. J Biomed Inform 6 (2006) 687-696
9. Lachin J.L. Statistical considerations in the intent-to-treat principle. Control Clin Trials 21 (2000) 167-189
10. Moher D., Dulberg C.S., and Wells G.A. Statistical power, sample size, and their reporting in randomized controlled trials. JAMA 272 (1994) 122-124
11. Kirby A.J., Galai N., and Munoz A. Sample size estimation using repeated measurements on biomarkers as outcomes. Control Clin Trials 15 (1994) 165-172
12. Ahu C., Overall J., and Tonidandel S. Sample size and power calculations in repeated measurement analysis. Comput Methods Programs Biomed 64 2 (2001) 121-124
13. Mayer-Hamblett N., and Kronmal R.A. Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting. Contemp Clin Trials 26 (2005) 2-16
14. Altman D.G., and Bland M.J. Treatment allocation by minimisation. BMJ 330 (2005) 843
15. Hagino A., Hamada C., Yoshinmura I., Ohashi Y., Sakamoto J., and Nakazato H. Statistical comparison of random allocations methods in cancer clinical trials. Contemp Clin Trials 25 6 (2004) 572-584